AASLD practice guidelines: Evaluation of the patient for liver transplantation

Hepatology

Volumn 41, Issue 6, 2005, Pages 1407-1432

  Murray, Karen F ^a   Carithers Jr , Robert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGILLE SYNDROME; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMYLOIDOSIS; AUTOIMMUNE HEPATITIS; BILE DUCT ATRESIA; BUDD CHIARI SYNDROME; CYSTIC FIBROSIS; EVALUATION; GLYCOGEN STORAGE DISEASE TYPE 4; HEMANGIOENDOTHELIOMA; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HEPATOBLASTOMA; HUMAN; HYPEROXALURIA; INTRAHEPATIC CHOLESTASIS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; NEUROENDOCRINE DISEASE; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TYROSINEMIA; WILSON DISEASE;

HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION;

EID: 20044372736     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20704     Document Type: Review

References (328)

1. Eddy DM. Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia, PA: American College of Physicians, 1996.
2. Position and policy statement: American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995;108: 925-926.
3. Woolf SH, Sox HC Jr. The Expert Panel on Preventive Services: continuing the work of the U.S. Preventive Services Task Force. Am J Prev Med 1991;7:326-330.
4. Belle SH, Porayko MK, Hoofnagle JH, Lake JR, Zetterman RK. Changes in quality of life after liver transplantation among adults. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). Liver Transpl Surg 1997;3:93-104.
5. Best JH, Veenstra DL, Geppert J. Trends in expenditures for Medicare liver transplant recipients. Liver Transpl 2001;7:858-862.
6. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001;120:749-762.
7. Otte JB, Ville-de-Goyet J, Reding R, Van-Obbergh L, Veyckemans F, Carlier MA, et al. Pediatric liver transplantation: from the full-size liver graft to reduced, split, and living related liver transplantation. Pediatr Surg Int 1998;13:308-318.
8. Malago M, Hertl M, Testa G, Rogiers X, Broelsch CE. Split-liver transplantation: future use of scarce donor organs. World J Surg 2002;26:275-282.
9. Gridelli B, Spada M, Petz W, Bertani A, Lucianetti A, Colledan M, et al. Split-liver transplantation eliminates the need for living-donor liver transplantation in children with end-stage cholestatic liver disease. Transplantation 2003;75:1197-1203.
10. Renz JF, Emond JC, Yersiz H, Ascher NL, Busuttil RW. Split-liver transplantation in the United States: outcomes of a national survey. Ann Surg 2004;239:172-181.
11. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. New Engl J Med 2002;346:1074-1082.
12. Surman OS. The ethics of partial-liver donation. New Engl J Med 2002; 346:1038.
13. Settmacher U, Theruvath T, Pascher A, Neuhaus P. Living-donor liver transplantation-European experiences. Nephrol Dial Transplant 2004; 19(Suppl 4):iv16-iv21.
14. Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 2002;73:616-622.
15. Evans RW. Liver transplants and the decline in deaths from liver disease. Am J Public Health 1997;87:868-869.
16. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. HEPATOLOGY 1989;10:1-7.
17. Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, Grambsch PM, Langworthy AL, et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patients visits. HEPATOLOGY 1994;20: 126-134.
18. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103:1893-1901.
19. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. HEPATOLOGY 1997;25:1049-1053.
20. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-648.
21. Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. New Engl J Med 1966;274:473-481.
22. Oellerich M, Burdelski M, Lautz H-U, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. HEPATOLOGY 1991;14:1029-1034.
23. Conn HO. A peek at the Child-Turcotte classification. HEPATOLOGY 1981;1:673-676.
24. Propst A, Propst T, Sangeri G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci 1995;40:1805-1815.
25. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997;3:628-637.
26. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000;31:864-871.
27. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
28. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
29. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10:7-15.
30. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
31. McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002;74:173-181.
32. Freeman RB, Rohrer RJ, Katz E, Lewis WD, Jenkins R, Cosimi AB, et al. Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time. Liver Transpl 2001;7: 173-178.
33. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112: 463-472.
34. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natutal history and prognosis factors. HEPATOLOGY 1987;7:122-128.
35. Andreu M, Sola R, Sitges SA, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-1138.
36. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
37. Starzl TE, Todo S, Gordon RD, Makowka L, Tzakis A, Iwatsuki S, et al. Liver transplantation in older patients. New Engl J Med 1987;316:484-485.
38. Zetterman RK, Belle SH, Hoofnagle JH, Lawlor S, Wei Y, Everhart J, et al. Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation 1998;66:500-506.
39. Collins BH, Pirsch JD, Becker YT, Hanaway MJ, Van der Werf WJ, D'Alessandro AM, et al. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 2000;70:780-783.
40. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 2003;3:1407-1412.
41. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996;2:426-430.
42. Plotkin JS, Benitez RM, Kuo PC, Njoku MJ, Ridge LA, Lim JW, et al. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. Liver Transpl Surg 1998;4:253-257.
43. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180-1188.
44. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 2000;69:2354-2356.
45. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. HEPATOLOGY 2003;37:192-197.
46. Collisson EA, Nourmand H, Fraiman MH, Cooper CB, Bellamy PE, Farmer DG, et al. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl 2002;8:925-931.
47. Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003;125:1042-1052.
48. Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997;72:44-53.
49. Santamaria F, Sarnelli P, Celentano L, Farina V, Vegnente A, Mansi A, et al. Noninvasive investigation of hepatopulmonary syndrome in children and adolescents with chronic cholestasis. Pediatr Pulmonol 2002;33:374-379.
50. Hadengue A, Benahyoun M, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
51. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. HEPATOLOGY 2003;37:401-409.
52. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3:494-500.
53. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
54. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002;8: 382-388.
55. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65:457-459.
56. Ramsay MA, Spikes C, East CA, Lynch K, Hein HA, Ramsay KJ, et al. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999;90:299-301.
57. Mair P, Kaehler CH, Pomaroli A, Schwarz B, Vogel W, Margreiter R. Orthotopic liver transplantation in a patient with severe portopulmonary hypertension. Acta Anaesthesiol Scand 2001;45:513-518.
58. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453-458.
59. Torregrosa M, Genesca J, Gonzalez A, Evangelista A, Mora A, Margarit C, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 2001;71:572-574.
60. Cotton CL, Gandhi S, Vaitkus PT, Massad MG, Benedetti E, Mrtek RG, et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl 2002;8:1051-1054.
61. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. HEPATOLOGY 2002;35:105-109.
62. Ehlers SL, Rodriguez JR, Widows MR, Reed AI, Nelson DR. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. Liver Transpl 2004;10:412-417.
63. Pungpapong S, Manzarbeitia C, Ortiz J, Reich DJ, Araya V, Rothstein KD, et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl 2002;8: 582-587.
64. Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997;48:159-164.
65. Bilbao I, Charco R, Balsells J, Lazaro JL, Hidalgo E, Llopart L, et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 1998;12:123-129.
66. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. HEPATOLOGY 2002;35:1179-1185.
67. Seu P, Wilkinson AH, Shaked A, Busuttil RW. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991;57:806-809.
68. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-430.
69. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002;8:91-109.
70. Grewal HP, Brady L, Cronin DC, Loss GE, Siegel CT, Oswald K, et al. Combined liver and kidney transplantation in children. Transplantation 2000;70:100-105.
71. Rogers J, Bueno J, Shapiro R, Scantlebury V, Mazariegos G, Fung J, et al. Results of simultaneous and sequential pediatric liver and kidney transplantation. Transplantation 2001;72:1666-1670.
72. Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002;8:193-211.
73. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004;10:648-653.
74. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316-323.
75. Floreani A, Mega A, Tizian L, Burra P, Boccagni P, Baldo V, et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 2001;12:749-754.
76. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003;9:1166-1173.
77. Trautwein C, Possienke M, Schlitt HJ, Boker KH, Horn R, Raab R, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000;95:2343-2351.
78. Ragni MV, Bontempo FA, Lewis JH. Organ transplantation in HIV-positive patients with hemophilia. New Engl J Med 1990;322:1886-1887.
79. Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994;19:854-859.
80. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998;42:744-749.
81. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003;9:239-247.
82. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76:370-375.
83. Schvarcz R, Rudbeck G, Soderdahl G, Stahle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69:2194-2195.
84. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999;68:307-309.
85. Tolan DJ, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. New Engl J Med 2001;345:1781.
86. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001;72:1684-1688.
87. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003;75:425-429.
88. Yerdel MA, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000;69: 1873-1881.
89. Manzanet G, Sanjuan F, Orbis P, Lopez R, Moya A, Juan M, et al. Liver transplantation in patients with portal vein thrombosis. Liver Transpl 2001;7:125-131.
90. Sobhonslidsuk A, Reddy KR. Portal vein thrombosis: a concise review. Am J Gastroenterol 2002;97:535-541.
91. Mitchell A, John PR, Mayer DA, Mirza DF, Buckels JA, de Ville dG. Improved technique of portal vein reconstruction in pediatric liver transplant recipients with portal vein hypoplasia. Transplantation 2002;73: 1244-1247.
92. Smith PA, Klein AS, Heath DG, Chavin K, Fishman EK. Dual-phase spiral CT angiography with volumetric 3D rendering for preoperative liver transplant evaluation: preliminary observations. J Comput Assist Tomogr 1998;22:868-874.
93. Cheng YF, Chen CL, Jawan B, Huang TL, Chen TY, Chen YS, et al. Multislice computed tomography angiography in pediatric liver transplantation. Transplantation 2003;76:353-357.
94. Eubank WB, Wherry KL, Maki JH, Sahin H, Funkhouser CP, Schmiedl UP. Preoperative evaluation of patients awaiting liver transplantation: comparison of multiphasic contrast-enhanced 3D magnetic resonance to helical computed tomography examinations. J Magn Reson Imaging 2002;16:565-575.
95. Erbay N, Raptopoulos V, Pomfret EA, Kamel IR, Kruskal JB. Living donor liver transplantation in adults: vascular variants important in surgical planning for donors and recipients. AJR Am J Roentgenol 2003; 181:109-114.
96. Kanchana TP, Kaul V, Manzarbeitia C, Reich DJ, Hails KC, Munoz SJ, et al. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002;8:778-782.
97. Liu LU, Schiano TD, Lau N, O'Rourke M, Min AD, Sigal SH, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant 2003;3:1273-1277.
98. Weinrieb RM, Barnett R, Lynch KG, DePiano M, Atanda A, Olthoff KM. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004;10:97-106.
99. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:886-897.
100. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002;36: S35-S46.
101. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
102. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-1619.
103. Kim WR. The burden of hepatitis C in the United States. HEPATOLOGY 2002;36:S30-S34.
104. Gane EJ, Portman BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. New Engl J Med 1996;334:815-820.
105. Shuhart MC, Bronner MP, Gretch DR, Thomassen LV, Wartelle CF, Tateyama H, et al. Histological and clinical outcome after liver transplantation for hepatitis C. HEPATOLOGY 1997;26:1646-1652.
106. Boker KHW, Dalley G, Bahr M, Maschek H, Tillmann HL, Trautwein C, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. HEPATOLOGY 1997;25:203-210.
107. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684.
108. Charlton M. Patient and graft survival following liver transplantation for hepatitis C: much ado about something. Gastroenterology 2002;122: 1162-1165.
109. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
110. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8:S14-S18.
111. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-561.
112. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650.
113. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-1144.
114. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:S90-S94.
115. Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34: 1225-1241.
116. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. HEPATOLOGY 2001;33:424-432.
117. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. HEPATOLOGY 2000;31:207-210.
118. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. HEPATOLOGY 2001;34:411-416.
119. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123:719-727.
120. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Engl J Med 2003;348:808-816.
121. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003;348:800-807.
122. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
123. Peters MG, Hann HH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
124. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer J, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B. Gastroenterology 1995;109: 908-916.
125. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-1121.
126. Todo S, Demetris AJ, Van Thiel DH, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. HEPATOLOGY 1991;13:619-626.
127. O'Grady JG, Smith JM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after liver transplantation: serological and clinical implications. J Hepatol 1992;14:104-111.
128. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. HEPATOLOGY 2000;32:1189-1195.
129. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002;8:S67-S73.
130. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235:611-619.
131. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. HEPATOLOGY 2002;35:1528-1535.
132. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24(Suppl 1):55-62.
133. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. HEPATOLOGY 2002;36:479-497.
134. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis 2002;22:379-386.
135. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18:62-69.
136. Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7:302-310.
137. Molmenti EP, Netto GJ, Murray NG, Smith DM, Molmenti H, Crippin JS, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002;8:519-526.
138. Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52:893-897.
139. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68:253-256.
140. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. HEPATOLOGY 2001;34:464-470.
141. Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. HEPATOLOGY 2002;35:349-356.
142. Cattan P, Berney T, Conti F, Calmus Y, Homberg JC, Houssin D, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int 2002;15:34-38.
143. Bahar RJ, Yanni GS, Martin MG, McDiarmid SV, Vargas JH, Gershman GB, et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 2001;72:829-833.
144. Birnbaum AH, Benkov KJ, Pittman NS, McFarlane FY, Rosh JR, Le-Leiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997;25:20-25.
145. Kim WR, Brown RS Jr., Terrault NA, El Serag H. Burden of liver disease in the United States: summary of a workshop. HEPATOLOGY 2002;36: 227-242.
146. Powell WJ, Klatskin G. Duration and survival in patients with Laennec's cirrhosis. Am J Med 1968;44:406-420.
147. Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981;80:1405-1409.
148. Veldt BJ, Laine F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, Moirand R. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002;36:93-98.
149. Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997;3:220-226.
150. Poynard T, Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multicentre group. J Hepatol 1999;30:1130-1137.
151. Miguet JP, Vanlemmens C, Milan C, Messner M, Minello A, Bocage L, et al. Impact of liver transplantation on survival in Pugh B alcoholic cirrhotic patients: a multicenter randomized trial [Abstract]. HEPATOLOGY 2003;38(Suppl 1):90A.
152. Wiesner RH, Lombardero M, Lake JR, Everhart J, Detre KM. Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes. Liver Transpl Surg 1997;3:231-239.
153. Pereira SP, Williams R. Liver transplantation for alcoholic liver disease at King's College Hospital: survival and quality of life. Liver Transpl Surg 1997;3:245-250.
154. Belle SH, Beringer KC, Detre KM. Liver transplantation for alcoholic liver disease in the United States: 1988 to 1995. Liver Transpl Surg 1997;3:212-219.
155. Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulin. HEPATOLOGY 1996;23:240-248.
156. Bathgate AJ, Hynd P, Sommerville D, Hayes PC. The prediction of acute cellular rejection in orthotopic liver transplantation. Liver Transpl Surg 1999;5:475-479.
157. Osorio RW, Ascher NL, Avery M, Bacchetti P, Roberts JP, Lake JR. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. HEPATOLOGY 1994;20:105-110.
158. Lucey MR, Carr K, Beresford TP, Fisher LR, Shieck V, Brown KA, et al. Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. HEPATOLOGY 1997;25:1223-1227.
159. Campbell DA Jr., Punch JD. Monitoring for alcohol use relapse after liver transplantation for alcoholic liver disease. Liver Transpl Surg 1997;3: 300-303.
160. Buis CI, Wiesner RH, Krom RA, Kremers WK, Wijdicks EF. Acute confusional state following liver transplantation for alcoholic liver disease. Neurology 2002;59:601-605.
161. Showstack J, Katz PP, Lake JR, Brown RS Jr., Dudley RA, Belle S, et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA 1999;281:1381-1386.
162. Lewis MB, Howdle PD. Neurologic complications of liver transplantation in adults. Neurology 2003;61:1174-1178.
163. Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001;72:619-626.
164. Lee RG. Recurrence of alcoholic liver disease after liver transplantation. Liver Transpl Surg 1997;3:292-295.
165. Pasha TM, Dickson ER. Survival algorithms and outcome analysis in primary biliary cirrhosis. Semin Liver Dis 1997;17:147-158.
166. Liermann Garcia RF, Evangelista GC, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. HEPATOLOGY 2001;33:22-27.
167. Tinmouth J, Tomlinson G, Heathcote EJ, Lilly L. Benefit of transplantation in primary biliary cirrhosis between 1985-1997. Transplantation 2002;73:224-227.
168. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. HEPATOLOGY 2000;31:1005-1013.
169. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001;13:1393-1394.
170. Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. New Engl J Med 1995;332:924-933.
171. Harnois DM, Lindor KD. Primary sclerosing cholangitis: evolving concepts in diagnosis and treatment. Dig Dis Sci 1997;15:23-41.
172. Lee YM, Kaplan MM. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002;97:528-534.
173. Abu-Elmagd KM, Malinchoc M, Dickson ER, Fung JJ, Murtaugh PA, Langworthy AL, et al. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet 1993;177:335-344.
174. Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. HEPATOLOGY 1995;22:451-457.
175. Ricci P, Therneau TM, Malinchoc M, Benson JT, Petz JL, Klintmalm GB, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. HEPATOLOGY 1997;25:672-677.
176. Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997;225:472-481.
177. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. HEPATOLOGY 1999;30:1121-1127.
178. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004;99:538-542.
179. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710-1717.
180. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995;117: 146-155.
181. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. HEPATOLOGY 1999;29:1050-1056.
182. Fabia R, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998;176:265-269.
183. Loftus EV Jr., Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. HEPATOLOGY 1998;27:685-690.
184. Davenport M, Kerkar N, Mieli VG, Mowat AP, Howard ER. Biliary atresia: the King's College Hospital experience (1974-1995). J Pediatr Surg 1997;32:479-485.
185. Ohi R, Ibrahim M. Biliary atresia. Semin Pediatr Surg 1992;1:115-124.
186. Otte JB, de Ville dG, Reding R, Hausleithner V, Sokal E, Chardot C, et al. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: a review. HEPATOLOGY 1994;20:41S-48S.
187. Van-der-Werf W-J, D'Alessandro AM, Knechtle SJ, Pilli G, Hoffmann RM, Judd RH, et al. Infant pediatric liver transplantation results equal those for older pediatric patients. J Pediatr Surg 1998;33:20-23.
188. Laurent J, Gauthier F, Bernard O, Hadchouel M, Odievre M, Valayer J, et al. Long-term outcome after surgery for biliary atresia. Study of 40 patients surviving for more than 10 years. Gastroenterology 1990;99: 1793-1797.
189. Woodle ES, Millis JM, So SK, McDiarmid SV, Busuttil RW, Esquivel CO, et al. Liver transplantation in the first three months of life. Transplantation 1998;66:606-609.
190. Diem HV, Evrard V, Vinh HT, Sokal EM, Janssen M, Otte JB, et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. Transplantation 2003;75:1692-1697.
191. Sandler AD, Azarow KS, Superina RA. The impact of a previous Kasai procedure on liver transplantation for biliary atresia. J Pediatr Surg 1997; 32:416-419.
192. Alagille D. Alagille syndrome today. Clin Invest Med 1996;19:325-330.
193. Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001;49:431-435.
194. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. HEPATOLOGY 1999;29:822-829.
195. Molmenti EP, Squires RH, Nagata D, Roden JS, Molmenti H, Fasola CG, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003;7:93-97.
196. Balistreri WF. Intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2002;35:S17-S23.
197. Bezerra JA, Balistreri WF. Intrahepatic cholestasis: order out of chaos. Gastroenterology 1999;117:1496-1498.
198. Kurbegov AC, Setchell KD, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 2003;125:1227-1234.
199. Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, et al. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr Transplant 1999;3:219-224.
200. Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003; 39:447-452.
201. Kayler LK, Rasmussen CS, Dykstra DM, Punch JD, Rudich SM, Magee JC, et al. Liver transplantation in children with metabolic disorders in the United States. Am J Transplant 2003;3:334-339.
202. Marcus N, Teckman JH, Perlmutter DH. Alpha1-antitrypsin deficiency: from genotype to childhood disease. J Pediatr Gastroenterol Nutr 1998; 27:65-74.
203. Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand 1988;77:847-851.
204. Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. HEPATOLOGY 1995;22:514-517.
205. Perlmutter DH. Alpha-1-antitrypsin deficiency. Semin Liver Dis 1998; 18:217-225.
206. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. New Engl J Med 1976;294:1316-1321.
207. Volpert D, Molleston JP, Perlmutter DH. Alpha1-antitrypsin deficiency-associated liver disease progresses slowly in some children. J Pediatr Gastroenterol Nutr 2000;31:258-263.
208. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996;8:989-994.
209. Esquivel CO, Vicente E, Van Thiel DH, Gordon R, Marsh W, Makowka L, et al. Orthotopic liver transplantation for alpha-1-antitrypsin deficiency: an experience in 29 children and ten adults. Transplant Proc 1987;19:3798-3802.
210. Vennarecci G, Gunson BK, Ismail T, Hubscher SG, Kelly DA, McMaster P, et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. Transplantation 1996;61:1488-1495.
211. Francavilla R, Castellaneta SP, Hadzic N, Chambers SM, Portmann B, Tung J, et al. Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. J Hepatol 2000;32: 986-992.
212. Prachalias AA, Kalife M, Francavilla R, Muiesan P, Dhawan A, Baker A, et al. Liver transplantation for alpha-1-antitrypsin deficiency in children. Transpl Int 2000;13:207-210.
213. Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991;100:762-767.
214. Schilsky ML. Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis 1996;16:83-95.
215. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. HEPATOLOGY 2003;37:1475-1492.
216. Sokol RJ, Francis PD, Gold SH, Ford DM, Lum GM, Ambruso DR. Orthotopic liver transplantation for acute fulminant Wilson disease. J Pediatr 1985;107:549-552.
217. Bellary S, Hassanein T, Van-Thiel DH. Liver transplantation for Wilson's disease. J Hepatol 1995;23:373-381.
218. Schumacher G, Mueller AR, Platz KP, Neuhaus R, Bechstein WO, Becker M, et al. Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. Transplant Proc 1996;28:3099-3100.
219. Guarino M, Stracciari A, D'Alessandro R, Pazzaglia P. No neurological improvement after liver transplantation for Wilson's disease. Acta Neurol Scand 1995;92:405-408.
220. Eghtesad B, Nezakatgoo N, Geraci LC, Jabbour N, Irish WD, Marsh W, et al. Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg 1999;5:467-474.
221. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
222. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.
223. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995;127:700-704.
224. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120: 1183-1192.
225. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002;35:373-379.
226. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003;37:917-923.
227. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
228. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. HEPATOLOGY 2004;39:770-778.
229. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999;29:664-669.
230. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
231. Ratziu V, Bonyhay L, Di M, V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002;35:1485-1493.
232. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373.
233. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
234. Duchini A, Brunson ME. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001;72:156-159.
235. Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RA, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997; 3:359-364.
236. Heneghan MA, Zolfino T, Muiesan P, Portmann BC, Rela M, Heaton ND, et al. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl 2003;9:921-928.
237. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33:1098-1104.
238. Mainous AG III, Gill JM, Pearson WS. Should we screen for hemochromatosis? An examination of evidence of downstream effects on morbidity and mortality. Arch Intern Med 2002;162:1769-1774.
239. Asberg A, Hveem K, Kruger O, Bjerve KS. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol 2002;37:719-724.
240. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
241. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. New Engl J Med 1985;313: 1256-1262.
242. Kowdley KV, Hassanein T, Kaur S, Farrell FJ, Van-Thiel DH, Keeffe EB, et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transpl Surg 1995;1:237-241.
243. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997; 112:882-888.
244. Deugnier Y, Turlin B, le Quilleuc D, Moirand R, Loreal O, Messner M, et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol 1997;21:669-675.
245. Cotler SJ, Bronner MP, Press RD, Carlson TH, Perkins JD, Emond MJ, et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 1998;29:257-262.
246. Fiel MI, Schiano TD, Bodenheimer HC, Thung SN, King TW, Varma CR, et al. Hereditary hemochromatosis in liver transplantation. Liver Transpl Surg 1999;5:50-56.
247. Brandhagen DJ, Alvarez W, Therneau TM, Kruckeberg KE, Thibodeau SN, Ludwig J, et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. HEPATOLOGY 2000;31:456-460.
248. Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-561.
249. Farrell FJ, Nguyen M, Woodley S, Imperial JC, Garcia KR, Man K, et al. Outcome of liver transplantation in patients with hemochromatosis. HEPATOLOGY 1994;20:404-410.
250. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl Surg 1999;5:369-374.
251. Stuart KA, Fletcher LM, Clouston AD, Lynch SV, Purdie DM, Kerlin P, et al. Increased Hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation. HEPATOLOGY 2000;32:1200-1207.
252. Keeffe EB. Liver transplantation in patients with hepatic iron overload: favorable or unfavorable outcome? HEPATOLOGY 2000;32:1396-1398.
253. Poulos JE, Bacon BR. Liver transplantation for hereditary hemochromatosis. Dig Dis Sci 1996;14:316-322.
254. Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transpl 2001;7:663-672.
255. Crawford DH, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, et al. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. HEPATOLOGY 2004;39:1655-1662.
256. Murray KF, Kowdley KV. Neonatal hemochromatosis. Pediatrics 2001; 108:960-964.
257. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998;21:507-517.
258. Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999;158(Suppl 2):S49-S54.
259. Matern D, Starzl TE, Arnaout W, Barnard J, Bynon JS, Dhawan A, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999;158(Suppl 2):S43-S48.
260. Suhr OB, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl 2002;8:787-794.
261. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123(Pt 7):1495-1504.
262. Latta K, Brodehl J. Primary hyperoxaluria type I. Eur J Pediatr 1990;149: 518-522.
263. van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 2003;18:273-279.
264. Langman CB. The optimal approach to the patient with oxalosis. Adv Ren Replace Ther 2001;8:214-222.
265. Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. New Engl J Med 1994;331:1553-1558.
266. Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU. Renal allograft survival in patients with oxalosis. Transplantation 2002;74:707-710.
267. Kayler LK, Merion RM, Lee S, Sung RS, Punch JD, Rudich SM, et al. Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 2002;6:295-300.
268. Yorifuji T, Muroi J, Uematsu A, Nakahata T, Egawa H, Tanaka K. Living-related liver transplantation for neonatal-onset propionic acidemia. J Pediatr 2000;137:572-574.
269. van't Hoff W, McKiernan PJ, Surtees RA, Leonard JV. Liver transplantation for methylmalonic acidaemia. Eur J Pediatr 1999;158(Suppl 2): S70-S74.
270. Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV. Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J Pediatr 2002;140:261-263.
271. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
272. Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003;238:315-321.
273. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
274. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. HEPATOLOGY 1999;30:1434-1440.
275. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. HEPATOLOGY 1993;18:1121-1126.
276. Curley SA, Izzo F, Ellis LM, Nicolas VJ, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381-391.
277. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
278. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. HEPATOLOGY 2002;35:1164-1171.
279. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. HEPATOLOGY 2003;37:429-442.
280. Iwatsuki S, Gordon RD, Shaw BW Jr., Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg 1985;202-4:401-407.
281. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311-322.
282. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 1996;334:693-699.
283. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004;10:36-4l.
284. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003;21:4329-4335.
285. Srinivasan P, McCall J, Pritchard J, Dhawan A, Baker A, Vergani GM, et al. Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation 2002;74:652-655.
286. El Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. HEPATOLOGY 2004; 39:798-803.
287. Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 1999; 85:562-582.
288. Ben-Haim M, Roayaie S, Ye MQ, Thung SN, Emre S, Fishbein TA, et al. Hepatic epithelioid hemangioendothelioma: resection or transplantation, which and when? Liver Transpl Surg 1999;5:526-531.
289. Sharif K, English M, Ramani P, Alberti D, Otte JB, McKiernan P, et al. Management of hepatic epithelioid haemangio-endothelioma in children: what option? Br J Cancer 2004;90:1498-1501.
290. Goldstein RM, Stone M, Tillery GW, Senzer N, Levy M, Husberg BS, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993;166:768-771.
291. Hassoun Z, Gores GJ, Rosen CB. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am 2002;11:909-921.
292. Trey C, Lipworth L, Chalmers TC, Davidson CS, Gottlieb LS, Popper H, et al. Fulminant hepatic failure. Presumable contribution to halothane. New Engl J Med 1968;279:798-801.
293. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23:217-226.
294. Lee WM. Management of acute liver failure. Semin Liver Dis 1996;16: 369-378.
295. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192.
296. O'Grady J, Alexander G, Hayllar K. Early indicators of prognosis in fulminant hepatitic failure. Gastroenterology 1989;97:439-445.
297. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003;31:299-305.
298. Bismuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1997:16:415-425.
299. McCashland TM, Shaw BW Jr., Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis 1996;16:427-433.
300. Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, et al. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 2003; 237:666-675.
301. Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996;16:379-388.
302. McCormick PA, Treanor D, McCormack G, Farrell M. Early death from paracetamol (acetaminophen) induced fulminant hepatic failure without cerebral oedema. J Hepatol 2003;39:547-551.
303. Acharya J, Westwood NB, Sawyer BM, Messinezy M, Burroughs AK, Mehta AB, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995; 55:315-321.
304. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48: 264-268.
305. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. HEPATOLOGY 2000;31:587-591.
306. Ganger DR, Klapman JB, McDonald V, Matalon TA, Kaur S, Rosenblate H, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: review of indications and problems. Am J Gastroenterol 1999;94:603-608.
307. Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 1999;19:457-473.
308. Orloff MJ, Daily PO, Orloff SL, Girard B, Orloff MS. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg 2000; 232:340-352.
309. Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg 2001;233:522-527.
310. Emre A, Kalayci G, Ozden I, Bilge O, Acarli K, Kaymakoglu S, et al. Mesoatrial shunt in Budd-Chiari syndrome. Am J Surg 2000;179:304-308.
311. Saigal S, Norris S, Srinivasan P, Muiesan P, Rela M, Heaton N, et al. Successful outcome of orthotopic liver transplantation in patients with preexisting malignant states. Liver Transpl 2001;7:11-15.
312. Ringe B, Lang H, Oldhafer K-J, Gebel M, Flemming P, Georgii A, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. HEPATOLOGY 1995;21:1337-1344.
313. Srinivasan P, Rela M, Prachalias A, Muiesan P, Portmann B, Mufti GJ, et al. Liver transplantation for Budd-Chiari syndrome. Transplantation 2002;73:973-977.
314. Mahmoud AE, Helmy AS, Billingham L, Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997;9: 485-489.
315. Langnas AN. Budd-Chiari syndrome: decisions, decisions. Liver Transpl Surg 1997;3:443-445.
316. Olzinski AT, Sanyal AJ. Treating Budd-Chiari Syndrome: making rational choices from a myriad of options. J Clin Gastroenterol 2000;30:155-161.
317. Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg 2004;187:39-46.
318. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231-242.
319. Olausson M, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B, et al. Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002;26:998-1004.
320. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004;8:208-212.
321. Jeyarajah DR, Gonwa TA, Testa G, Abbasoglu O, Goldstein R, Husberg BS, et al. Liver and kidney transplantation for polycystic disease. Transplantation 1998;66:529-532.
322. Chui AK, Koorey D, Pathania OP, Rao AR, McCaughan GW, Sheil AG. Polycystic disease: a rare indication for combined liver and kidney transplantation. Hong Kong Med J 2000;6:116-118.
323. Koyama I, Fuchinoue S, Urashima Y, Kato Y, Tsuji K, Kawase T, et al. Living related liver transplantation for polycystic liver disease. Transpl Int 2002;15:578-580.
324. Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002;236:713-721.
325. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002;8:313-322.
326. Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 2003;9:897-904.
327. Sieders E, Peeters PM, TenVergert EM, de Jong KP, Porte RJ, Zwaveling JH, et al. Retransplantation of the liver in children. Transplantation 2001;71:90-95.
328. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. HEPATOLOGY 2004;39:230-238.